THERAPY DOSSIER · th-354a65aa2fcb

Soluble apyrase; human CD39 transgenic overexpression studied as a separate comparison arm

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28198766 ↗2017Mixed findings

The Differential Effect of Apyrase Treatment and hCD39 Overexpression on Chronic Renal Fibrosis After Ischemia-Reperfusion Injury

MouseIschaemia-reperfusionRenalC57BL/6 (from MeSH indexing); human CD39 transgenic line and wild-type littermatesmale (from MeSH indexing)Single dose administered before ischaemia-reperfusion injury

Model: Unilateral renal ischaemia-reperfusion injury

A single dose of soluble apyrase before ischaemia-reperfusion injury reduced acute renal injury at 24 h and renal fibrosis at 4 weeks versus vehicle, and lowered renal ATP, ADP and AMP but not adenosine during ischaemia. In contrast, human CD39 transgenic mice were protected from acute injury at 24…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…